{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:45:55Z","timestamp":1761864355380,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Initial studies that described the novel coronavirus (COVID-19) reported increased morbidity and mortality in patients with cancer. Of this group, patients with hematologic malignancies (HM) had the highest disease severity and death rates. Subsequent studies have attempted to better describe how COVID-19 affects patients with HM. However, these studies have yielded variable and often contradictory results. We present our single-institution experience with patients with HM who were diagnosed with COVID-19 from March 2020 to March 2021. We report 62 total cases with 10 patients who died during this time. The overall mortality was 16.1%. Mortality during the first two waves of COVID was 27.8% and 25%. Mortality during the third wave of COVID was 10%. The median age of patients was 67 years (range 20-89 years). 55% of patients had lymphoid malignancies and the majority had active disease at the time of diagnosis with COVID-19. 87% of patients had more than one co-morbidity. Important co-morbidities included cardiovascular disease and smoking history. 38.7% of patients had asymptomatic or mild disease, 54.8% required hospitalization, and 17.5% required ICU level care. In patients who required ICU level care, the mortality was 60%.<\/jats:p>","DOI":"10.3389\/fonc.2021.740320","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T18:46:56Z","timestamp":1635446816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19 in Patients With Hematologic Malignancies: A Single Center Retrospective Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Xuejun Alice","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam F.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","unstructured":"Situation by Country, Territory & Area"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer Patients in SARS-Cov-2 Infection: A Nationwide Analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients With Cancer Appear More Vulnerable to SARS-COV-2: A Multi-Center Study During the COVID-19 Outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discovery"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.02.004","article-title":"Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient","volume":"33","author":"Fontana","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5501\/wjv.v10.i3.97","article-title":"Impact of COVID-19 in Patients With Lymphoid Malignancies","volume":"10","author":"Riches","year":"2021","journal-title":"World J Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0853-6","article-title":"COVID-19 in Persons With Chronic Myeloid Leukaemia","volume":"34","author":"Li","year":"2020","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006288","article-title":"The BTK Inhibitor Ibrutinib may Protect Against Pulmonary Injury in COVID-19\u2013Infected Patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16863","article-title":"Protective Role of Bruton Tyrosine Kinase Inhibitors in Patients With Chronic Lymphocytic Leukaemia and COVID-19","volume":"190","author":"Thibaud","year":"2020","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100775","article-title":"When Hematologic Malignancies Meet COVID-19 in the United States: Infections, Death and Disparities","volume":"47","author":"Wang","year":"2021","journal-title":"Blood Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in Persons With Haematological Cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2352-3026(20)30251-9See","article-title":"Clinical Characteristics and Risk Factors Associated With COVID-19 Severity in Patients With Haematological Malignancies in Italy: A Retrospective, Multicentre, Cohort Study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of Patients With Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 3377 Patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B13","unstructured":"Trends in Number of COVID-19 Cases and De in the US Reported to CDC, by State\/Territory"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003170","article-title":"Outcomes of Patients With Hematologic Malignancies and COVID-19: A Report From the ASH Research Collaborative Data Hub","volume":"4","author":"Wood","year":"2020","journal-title":"Blood Adv"},{"volume-title":"Framework for Equitable Allocation of COVID-19 Vaccine","year":"2020","key":"B15"},{"volume-title":"People With Certain Medical Conditions","year":"2020","key":"B16"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106233","article-title":"Tobacco Use as a Well-Recognized Cause of Severe COVID-19 Manifestations","volume":"176","author":"Gupta","year":"2021","journal-title":"Respir Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.740320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T18:47:00Z","timestamp":1635446820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.740320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":17,"alternative-id":["10.3389\/fonc.2021.740320"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.740320","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"740320"}}